Nxera Pharma Co., Ltd. (SOLTF)
| Previous close | 9.72 |
| Open | 9.23 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.23 - 9.30 |
| 52-week range | 8.56 - 22.78 |
| Volume | |
| Avg. volume | 896 |
| Market cap | 838.111M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Mar 2015 |
| 1y target est | N/A |
GlobeNewswireNxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share Issuance”) under the 19th to 22nd Restricted Stock Unit (“RSU”) Plan and determined the payment amount and other matters of issuance of new shares under the 12th RSU and 14th RSU as follows. 1. Issuance of new shares under the RSU PlanThe resolution on the Share Issuance under the
- GlobeNewswire
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of a long-term preclinical toxicity program to support safe, chronic dosing of NBI-1117568 in future clinical trials triggers a $15 million payment to Nxera from Neurocrine Biosciences Tokyo, Japan and Cambridge, UK, 16 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly
- GlobeNewswire
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)PIVLAZ™ will become commercially available in South Korea in early 2025 Tokyo, Japan and Cambridge, UK, 15 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces that its operating business Nxera Pharma Korea (“NPK”) has entered into an exclusive supply and distributi
